Dr Yuen Yee Cheng

Clinical Senior Lecturer
Concord Clinical School

Telephone +61 2 9767 9800

Curriculum vitae Curriculum vitae

Map

Biographical details

Dr Cheng is a recognised expert in cancer epigenetics. She has been invited to speak at the upcoming 7th Australian Epigenetic Conference 2017 (Brisbane) and a lead editor of the journals Disease Markers and Journal of Nucleic Acids. Since joining the Asbestos Diseases Research Institute (ADRI) in March 2010, she has established a research theme based on epigenetic gene regulation of tumour suppressors in Malignant Pleural Mesothelioma (MPM).

Dr Cheng has contributed to the “TargomiR” project resulting in the world’s first clinical trial of microRNA replacement in mesothelioma (https://clinicaltrials.gov/ct2/show/NCT02369198).

She has extensive experience in mentoring and training post-graduate students. Her current role, including supervision of research scientists, PhD, Masters and Honours students in their lab work as well as their research projects. She is also strongly involved in development of assays for molecular diagnostics in the clinical setting. She is a consultant scientist including the characterisation and process of clinical samples in ADRI’s Biobank – a substantial collection of MPM tumours in Australia. One of the milestones of her meticulous molecular biology techniques was curating MPM samples from Australia as part of The Cancer Genome Atlas (TCGA) project on mesothelioma, www.cancergenome.nih.gov – an NIH initiative to catalogue genetic mutations responsible for cancer.

Dr Cheng has published widely in various disciplines. To date, she co-authored 36 peer-reviewed journal articles (including 11 first author and two corresponding authors), h-index 21(i10-index 25) with a total ISI citation of over 1600. She has presented >50 peer-reviewed abstracts at international and national conferences since joining ADRI in 2010. In 2012 she was the recipient of a prestigious Young Investigator Travel Award at the 11th International Mesothelioma Interest Group (iMig) Conference in Boston.

Research interests

Functional cancer epigenetics

Molecular diagnostics

DNA methylation

MicroRNA

Non-invasive diagnostic

Tumour suppressor

Teaching and supervision

Molecular biology and functional studies at graduate level and

PhD

M.Phil

Honours

Associations

American Association for Cancer Research (AACR) (2003-to-date)

Sydney Catalyst (2010-to-date)

Thoracic Society of Australia & New Zealand (TSANZ) (2016-to-date)

Lung Foundation Australia (2010- to-date)

Awards and honours

Year

Award

Funding

2001

Best Basic Science Paper Award

The Hong Kong Orthopaedic Association Congress

2002

Best Poster Award

The Hong Kong Orthopaedic Association Congress

2005

Visiting Scientist Award

The Centre for Integrated Cancer Biology, Ohio State University

2010

Travel award

Australian Lung Cancer Conference

2012

Young Investigator Award

International Mesothelioma Interest Group Meeting

2016

Travel grant

Concord Clinical School

2016

Travel grant

Lung Foundation Australia

First Year

Application

Funding

No. of Years

Role

Amount ($)

2008

Small project funding and matching grant

The University of Hong Kong

2

Sole Chief Investigator

HKD 84,000

2010-2013

Fellowship

Asbestos Diseases Foundation Australia

3

Sole Chief Investigator

AUD 150,000

2016-2019

Project grant

Dust Diseases Board Australia

3

Investigator

AUD 249,000

2018-2021

Project grant

Dust Diseases Board Australia

3

Chief Investigator B and project co-ordinator

AUD 300,000

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Li, W., Hu, X., Yang, S., Wang, S., Zhang, C., Wang, H., Cheng, Y., Wang, Y., Liu, T., Song, K. (2018). A novel tissue-engineered 3D tumor model for anti-cancer drug discovery. Biofabrication, 11(1), 1-18. [More Information]
  • Linton, A., Cheng, Y., Griggs, K., Schedlich, L., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2018). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 118(6), e13. [More Information]
  • Rath, E., Cheng, Y., Pinese, M., Sarun, K., Hudson, A., Weir, C., Wang, Y., Hakansson, A., Howell, V., Liu, G., Reid, G., Church, W., et al (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PloS One, 13(8), 1-32. [More Information]
  • Johnson, T., Schelch, K., Cheng, Y., Williams, M., Sarun, K., Kirschner, M., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G., et al (2018). Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. [More Information]
  • Cheng, Y., Jin, H., Chan, M., Chu, W., Grusch, M. (2018). Epigenetic Biomarkers in Cancer. Disease Markers, 2018, 1-2. [More Information]
  • Sarun, K., Lee, K., Williams, M., Wright, C., Clarke, C., Cheng, N., Takahashi, K., Cheng, Y. (2018). Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures. International Journal of Molecular Sciences, 19(10), 1-16. [More Information]
  • Leygo, C., Williams, M., Jin, H., Chan, M., Chu, W., Grusch, M., Cheng, Y. (2017). DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer. Disease Markers, 2017 (3726595), 1-13. [More Information]
  • Williams, M., Cheng, Y., Blenkiron, C., Reid, G. (2017). Exploring Mechanisms of MicroRNA Downregulation in Cancer. MicroRNA, 1(6), 2-16.
  • Cheng, Y., Mok, E., Tan, S., Leygo, C., McLaughlin, C., George, A., Reid, G. (2017). SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. Disease Markers, 2017, 1-10. [More Information]
  • Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]
  • Cheng, Y., Wright, C., Kirschner, M., Williams, M., Sarun, K., Sytnyk, V., Leshchynska, I., Edelman, J., Vallely, M., McCaughan, B., van Zandwijk, N., Reid, G., et al (2016). KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 15(1), 1-12. [More Information]
  • Lin, R., Kirschner, M., Cheng, Y., van Zandwijk, N., Reid, G. (2016). MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 9, 44-49. [More Information]
  • Chau, D., Ng, K., Chan, T., Cheng, Y., Fong, B., Tam, S., Kwong, Y., Tse, E. (2015). Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. Journal of Hematology and Oncology, 8(1), 1-11. [More Information]
  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]
  • Cheng, A., Li, M., Kang, W., Cheng, Y., Chou, J., Lau, S., Go, M., Lee, C., Ling, T., Ng, E., et al (2013). Helicobacter pylori Causes Epigenetic Dysregulation of FOXD3 to Promote Gastric Carcinogenesis. Gastroenterology, 144(1), 122-133.e9. [More Information]
  • Lim, C., Prele, C., Cheah, H., Cheng, Y., Klebe, S., Reid, G., Watkins, D., Baltic, S., Thompson, P., Mutsaers, S. (2013). Mutational Analysis of Hedgehog Signaling Pathway Genes in Human Malignant Mesothelioma. PloS One, 8(6), 1-12. [More Information]
  • Reid, G., Pel, M., Kirschner, M., Cheng, Y., Amaro-Mugridge, N., Madrid-Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., van Zandwijk, N., et al (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. [More Information]
  • Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013). ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. [More Information]
  • Yu, J., Liang, Q., Wang, J., Cheng, Y., Wang, S., Poon, T., Go, M., Tao, Q., Chang, Z., Sung, J. (2013). Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene, 32(3), 307-317. [More Information]
  • Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]
  • Cheng, Y., Chau, D., Chan, T., Gill, H., Liang, R., Kwong, Y., Tse, E. (2010). Absence of NPM1 Promoter Hypermethylation in Human Myelodysplastic Syndrome. Journal of Clinical Pathology, 63(11), 1008-1011. [More Information]
  • Li, J., Ng, E., Ng, Y., Wong, C., Yu, J., Jin, H., Cheng, Y., Go, M., Cheung, P., Ebert, M., et al (2009). Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. British Journal of Cancer, 101(4), 691-698. [More Information]
  • Yu, J., Cheng, Y., Tao, Q., CHEUNG, K., Lam, C., Geng, H., Tian, L., Wong, Y., Tong, J., et al (2009). Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology, 136(2), 640-651. [More Information]
  • Liu, X., Lam, E., Wang, X., Zhang, J., Cheng, Y., Lam, Y., Ng, E., Yu, J., Chan, F., Jin, H., et al (2009). Promoter Hypermethylation Mediates Downregulation of Thiamine Receptor SLC19A3 in Gastric Cancer. Tumor Biology, 30(5), 242-248. [More Information]
  • Yu, J., Tao, Q., Cheng, Y., Lee, K., Ng, S., CHEUNG, K., Tian, L., Rha, S., Neumann, U., et al (2009). Promoter methylation of the Wnt/(beta)-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer, 115(1), 49-60. [More Information]
  • Yu, J., Tao, Q., CHEUNG, K., Jin, H., Poon, F., Wang, X., Li, H., Cheng, Y., Rocken, C., Ebert, M., et al (2008). Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology, 48(2), 508-518. [More Information]
  • Cheng, Y., Jin, H., Liu, X., Siu, J., Wong, Y., Ng, E., Yu, J., Leung, W., Sung, J., Chan, F. (2008). Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. British Journal of Cancer, 99(12), 2083-2087. [More Information]
  • Chen, B., Yu, J., Zeng, Z., Chu, W., Wong, C., Cheng, Y., Sung, J., Hu, P., Leung, W. (2008). Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncology Reports, 20(5), 1093-1097. [More Information]
  • Cheng, Y., Yu, J., Wong, Y., Man, E., To, K., Jin, V., Li, J., Tao, Q., Sung, J., Chan, F., et al (2007). Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. British Journal of Cancer, 97(7), 895-901. [More Information]
  • Leung, W., Man, E., Yu, J., Go, M., To, K., Yamaoka, Y., Cheng, Y., Ng, E., Sung, J. (2006). Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clinical Cancer Research, 12(10), 3216-3321. [More Information]

2018

  • Li, W., Hu, X., Yang, S., Wang, S., Zhang, C., Wang, H., Cheng, Y., Wang, Y., Liu, T., Song, K. (2018). A novel tissue-engineered 3D tumor model for anti-cancer drug discovery. Biofabrication, 11(1), 1-18. [More Information]
  • Linton, A., Cheng, Y., Griggs, K., Schedlich, L., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2018). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 118(6), e13. [More Information]
  • Rath, E., Cheng, Y., Pinese, M., Sarun, K., Hudson, A., Weir, C., Wang, Y., Hakansson, A., Howell, V., Liu, G., Reid, G., Church, W., et al (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PloS One, 13(8), 1-32. [More Information]
  • Johnson, T., Schelch, K., Cheng, Y., Williams, M., Sarun, K., Kirschner, M., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G., et al (2018). Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. [More Information]
  • Cheng, Y., Jin, H., Chan, M., Chu, W., Grusch, M. (2018). Epigenetic Biomarkers in Cancer. Disease Markers, 2018, 1-2. [More Information]
  • Sarun, K., Lee, K., Williams, M., Wright, C., Clarke, C., Cheng, N., Takahashi, K., Cheng, Y. (2018). Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures. International Journal of Molecular Sciences, 19(10), 1-16. [More Information]

2017

  • Leygo, C., Williams, M., Jin, H., Chan, M., Chu, W., Grusch, M., Cheng, Y. (2017). DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer. Disease Markers, 2017 (3726595), 1-13. [More Information]
  • Williams, M., Cheng, Y., Blenkiron, C., Reid, G. (2017). Exploring Mechanisms of MicroRNA Downregulation in Cancer. MicroRNA, 1(6), 2-16.
  • Cheng, Y., Mok, E., Tan, S., Leygo, C., McLaughlin, C., George, A., Reid, G. (2017). SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. Disease Markers, 2017, 1-10. [More Information]
  • Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]

2016

  • Cheng, Y., Wright, C., Kirschner, M., Williams, M., Sarun, K., Sytnyk, V., Leshchynska, I., Edelman, J., Vallely, M., McCaughan, B., van Zandwijk, N., Reid, G., et al (2016). KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 15(1), 1-12. [More Information]
  • Lin, R., Kirschner, M., Cheng, Y., van Zandwijk, N., Reid, G. (2016). MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 9, 44-49. [More Information]

2015

  • Chau, D., Ng, K., Chan, T., Cheng, Y., Fong, B., Tam, S., Kwong, Y., Tse, E. (2015). Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. Journal of Hematology and Oncology, 8(1), 1-11. [More Information]

2014

  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]

2013

  • Cheng, A., Li, M., Kang, W., Cheng, Y., Chou, J., Lau, S., Go, M., Lee, C., Ling, T., Ng, E., et al (2013). Helicobacter pylori Causes Epigenetic Dysregulation of FOXD3 to Promote Gastric Carcinogenesis. Gastroenterology, 144(1), 122-133.e9. [More Information]
  • Lim, C., Prele, C., Cheah, H., Cheng, Y., Klebe, S., Reid, G., Watkins, D., Baltic, S., Thompson, P., Mutsaers, S. (2013). Mutational Analysis of Hedgehog Signaling Pathway Genes in Human Malignant Mesothelioma. PloS One, 8(6), 1-12. [More Information]
  • Reid, G., Pel, M., Kirschner, M., Cheng, Y., Amaro-Mugridge, N., Madrid-Weiss, J., Williams, M., Wright, C., Edelman, J., Vallely, M., van Zandwijk, N., et al (2013). Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 24(12), 3128-3135. [More Information]
  • Cheng, Y., Kirschner, M., Cheng, N., Gattani, S., Klebe, S., Edelman, J., Vallely, M., McCaughan, B., Jin, H., van Zandwijk, N., Reid, G. (2013). ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 8(10), 1317-1328. [More Information]
  • Yu, J., Liang, Q., Wang, J., Cheng, Y., Wang, S., Poon, T., Go, M., Tao, Q., Chang, Z., Sung, J. (2013). Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene, 32(3), 307-317. [More Information]

2012

  • Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]

2010

  • Cheng, Y., Chau, D., Chan, T., Gill, H., Liang, R., Kwong, Y., Tse, E. (2010). Absence of NPM1 Promoter Hypermethylation in Human Myelodysplastic Syndrome. Journal of Clinical Pathology, 63(11), 1008-1011. [More Information]

2009

  • Li, J., Ng, E., Ng, Y., Wong, C., Yu, J., Jin, H., Cheng, Y., Go, M., Cheung, P., Ebert, M., et al (2009). Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. British Journal of Cancer, 101(4), 691-698. [More Information]
  • Yu, J., Cheng, Y., Tao, Q., CHEUNG, K., Lam, C., Geng, H., Tian, L., Wong, Y., Tong, J., et al (2009). Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology, 136(2), 640-651. [More Information]
  • Liu, X., Lam, E., Wang, X., Zhang, J., Cheng, Y., Lam, Y., Ng, E., Yu, J., Chan, F., Jin, H., et al (2009). Promoter Hypermethylation Mediates Downregulation of Thiamine Receptor SLC19A3 in Gastric Cancer. Tumor Biology, 30(5), 242-248. [More Information]
  • Yu, J., Tao, Q., Cheng, Y., Lee, K., Ng, S., CHEUNG, K., Tian, L., Rha, S., Neumann, U., et al (2009). Promoter methylation of the Wnt/(beta)-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer, 115(1), 49-60. [More Information]

2008

  • Yu, J., Tao, Q., CHEUNG, K., Jin, H., Poon, F., Wang, X., Li, H., Cheng, Y., Rocken, C., Ebert, M., et al (2008). Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology, 48(2), 508-518. [More Information]
  • Cheng, Y., Jin, H., Liu, X., Siu, J., Wong, Y., Ng, E., Yu, J., Leung, W., Sung, J., Chan, F. (2008). Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. British Journal of Cancer, 99(12), 2083-2087. [More Information]
  • Chen, B., Yu, J., Zeng, Z., Chu, W., Wong, C., Cheng, Y., Sung, J., Hu, P., Leung, W. (2008). Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncology Reports, 20(5), 1093-1097. [More Information]

2007

  • Cheng, Y., Yu, J., Wong, Y., Man, E., To, K., Jin, V., Li, J., Tao, Q., Sung, J., Chan, F., et al (2007). Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. British Journal of Cancer, 97(7), 895-901. [More Information]

2006

  • Leung, W., Man, E., Yu, J., Go, M., To, K., Yamaoka, Y., Cheng, Y., Ng, E., Sung, J. (2006). Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clinical Cancer Research, 12(10), 3216-3321. [More Information]

To update your profile click here. For support on your academic profile contact .